Chikungunya 04 Lindsey 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

21

Document text

National Center for Emerging and Zoonotic Infectious Diseases
Chronic arthralgia after chikungunya
Nicole Lindsey, MS
CDC Deputy Lead , Chikungunya Vaccines Work Group
Arboviral Diseases Branch
Centers for Disease Control and Prevention
Clinical outcomes of chikungunya virus disease
Acute symptoms typically resolve in 7 -10 days
Mortality is very rare
Significant proportion of patients have continued or recurrent arthralgia in 
months and years following acute illness
Additional long- term complications reported less frequently
–Fatigue
–Depression
–Alopecia−Impaired memory
−Sleep disorders
−Lowered quality of life
Chronic joint symptoms after chikungunya
Many published studies with high variability in results based on:
–Study methodology
–Definitions and ascertainment of symptoms
–Duration of follow up
–Characteristics of patient cohort (e.g., location, demographics)
Previous meta -analyses with varying outcomes and inclusion criteria
–None used outcome and criteria most of interest to guide vaccine 
recommendation process
Systematic review and meta -analysis
Objective to estimate percentage of patients with chronic arthralgia (≥3 
months) following chikungunya virus infection
Literature search for articles published Jan 1, 2000 –Oct 24, 2022, 
describing primary data on arthralgia following chikungunya infection
Excluded articles:
–Without laboratory confirmation of all infections 
–Specific subgroups (e.g., children, people with co -infections, large 
proportion of cases hospitalized for acute disease)
–Non -English language
Study selection process
1,167•
•
••••Articles identified through search. All ab stracts reviewed1,087 did not meet criteria and were excluded
80Articles with a full text review53 did not meet criteria and were excluded
27Articles met inclusion criteriaS tandardized data extraction into spreadsheet tool
Characteristics of 27 included studies (N=4,079)
Most clustered in 1 of 2 time periods (2005– 2006 and 2014– 2015)
23 communities with outbreaks, 4 travelers to outbreak locations
14 locations in Americas, 8 Indian Ocean, 4 Asia, 1 Europe
4 studies included control group of non- infected persons
Range of severity of illnesses (0 –33% hospitalized) 
Varied demographics of included participants
Chronic arthralgia following chikungunya virus disease*
0%10%20%30%40%50%60%70%80%90%100%
0 3 6 9 12 15 18 21 24 27 30 33 36Percentage with chronic arthralgia
Months after illness onset
*Some studies estimated proportion with chronic arthralgia at >1 time point
Chronic arthralgia following chikungunya virus disease*
0%10%20%30%40%50%60%70%80%90%100%
0 3 6 9 12 15 18 21 24 27 30 33 36Percentage with chronic arthralgia
Months after illness onset
*Some studies estimated proportion with chronic arthralgia at >1 time point
7 studies included accounting for a total of 733 patients
All included patients who sought healthcare 
Two traveler cohorts and five cohorts from communities with outbreaks
–Travelers to countries in Indian Ocean and Americas
–Outbreaks: Brazil, French Guiana, Martinique, Sint Maarten, Thailand
Predominance of females (range 52– 74%)
Range of study mean/median ages (35– 51 years)
Range of severity (hospitalization range 0 –17%)Arthralgia 3 months after chikungunya infection 
Arthralgia 3 months after chikungunya infection (N=7)
Study Location Sample Rate (95% CI )
Bocanegra 2016 Travelers to the Americas, 2014 -2015 34 50% (33, 67)
Simon 2007 Travelers to the Indian Ocean, 2005 -2006 47 86% (75, 95)
Bertolotti 2020 Martinique, 2014 167 55% (48, 62)
Benjamanukul 2021 Thailand, 2018 164 53% (46, 60)
Peters 2018 Sint Marteen, 2014 56 52% (39, 64)
Silva 2021 Brazil, 2014 -2016 153 43% (36, 50)
Bonifay 2018 French Guiana, 2014 112 42% (33, 51)
Summary estimate* 51% (44, 58)
0 20 40 60 80 100
*Random effects model
Arthralgia 6 months after chikungunya infection
9 studies included accounting for a total of 961 patients
All included patients who sought healthcare 
Three traveler cohorts and six cohorts from communities with outbreaks
–Travelers to countries in Indian Ocean
–Outbreaks: Bangladesh, French Guiana, Martinique, Mexico, 
Suriname, Thailand
Predominance of females (range 52– 68%)
Range of study mean/median ages (32– 60 years)
Range of severity (hospitalization range 0 –33%)
Arthralgia 6 months after chikungunya infection (N=9)
Study Location Sample Rate (95% CI )
Schilte 2013 Reunion Island, 2005 -2006 180 70% (63, 77)
Simon 2007 Travelers to Indian Ocean, 2005 -2006 47 48% (35, 63)
Feldstein 2017 USVI, 2014- 2015 165 44% (37, 52)
Murillo -Zamora 2017 Mexico, 2015 136 42% (34, 50)
Bertolotti 2020 Martinique, 2014 167 36% (29, 43)
Bonifay 2018 French Guiana, 2014 112 31% (23, 40)
van Genderen 2016 Suriname, 2013 90 22% (14, 31)
Taubitz 2007 Travelers to Indian Ocean, 2006 16 13% (0, 29)
Anwar 2020 Bangladesh, 2017 48 13% (0, 22)
Summary estimate* 35% (24, 47)
*Random effects model 0 20 40 60 80 100
Arthralgia 12 months after chikungunya infection
10 studies included accounting for a total of 1,539 patients
9 included patients who sought healthcare; 1 population- based sample
All cohorts from communities with outbreaks: Aruba, Bangladesh, Brazil, 
Grenada, Italy, Malaysia, Martinique, Reunion Island, US Virgin Islands (2)
Predominance of females (range 52– 73%)
Range of study mean/median ages (33– 60 years)
Range of severity (hospitalization range 0 –23%)
Arthralgia 12 months after chikungunya infection (N=10)
*Random effects modelStudy Location Sample Rate (95% CI )
de Moraes 2020 Brazil, 2016 -2018 107 61% (52, 70)
Moro 2012 Italy, 2007 250 61% (55, 67)
Schilte 2013 Reunion Island, 2005 -2006 180 58% (51, 65)
Heath 2018 Grenada, 2014 240 35% (29, 41)
Feldstein 2017 USVI, 2014- 2015 165 33% (26, 40)
Bertolotti 2020 Martinique, 2014 167 31% (24, 38)
Hennessey 2018 USVI, 2014- 2015 171 31% (24, 38)
Huits 2018 Aruba, 2014 171 26% (19, 32)
Mohd Zim 2013 Malaysia, 2008 40 23% (10, 35)
Anwar 2020 Bangladesh, 2017 48 19% (8, 30)
Summary estimate* 38% (29, 46)
0 20 40 60 80 100
Chronic arthralgia following chikungunya virus disease*
*Among 9 studies that estimated proportion with chronic arthralgia at >1 time point0%10%20%30%40%50%60%70%80%90%100%
0 3 6 9 12 15 18 21 24 27 30 33 36
Chronic arthralgia estimates among travelers (N=4)
Reference Location, Year N Population description 3m 6m 24m
Simon 2007 Indian Ocean, 2005 -2006 47French travelers treated at 
Lavaren Hospital in Marseilles 86% 48%
Larrieu 2010 Indian Ocean, 2005 -2006 29French travelers treated at 
University Hospital in Bordeaux 59%
Taubitz 2007 Indian Ocean, 2006 16German travelers treated at Institute of Trop Med in Hamburg 13%
Bocanegra 2016 Americas, 2014- 2015 34Spanish travelers who presented to public health 50%
Limitations
Variability in case definitions, populations included, findings
Almost all persons who seek healthcare for symptoms; not representative 
of all cases
Very few studies included control group to account for background rates of arthralgia in population
–Crude estimates from all studies used to calculate summary estimates
Chronic arthralgia in controlled studies
Soumahoro 2009 ( Reunion 2005- 2006)
–199 CHIKV+,  199 CHIKV-
–At 17m, CHIKV+ more joint pain than CHIKV -(53% vs 28%)
–Estimated 47% (95% CI 37% –55%) of pain in case -patients attributed to CHIK
Gerardin 2011 ( Reunion 2005- 2006)
–512 CHIKV+, 582 CHIKV-
–At 16m, CHIKV+ more likely to complain of musculoskeletal pain (43% vs 17%) 
–Estimated 60% (95% CI 52% -68%) of pain in case -patients attributed to CHIK
Chronic arthralgia in controlled studies (cont.)
Feldstein 2017 ( USVI 2014- 2015)
–165 CHIKV+, 167 CHIKV-
–At 6m, difference in arthralgia between case -patients and controls 32% (95% 
CI 24% –40%) after adjusting for age, sex, history of arthritis
–At 12m, adjusted difference was 19% (95% CI 11% –28%)
Hennessey 2018 (USVI 2014- 2015)
–171 CHIKV+, 338 CHIKV-
–At 12m, 31% case -patients, 26% of controls joint pain in last week
–Estimated 23% (95% CI 9% -37%) of continued joint pain in case -patients 
attributed to CHIK infection
Review of key points
A substantial proportion of patients who seek care for their acute illness have 
chronic arthralgia following chikungunya virus infection
–Estimated ~one -half have arthralgia at 3 months
–Rates decrease and ~one -third estimated with arthralgia at 12 months
All proportions likely overestimates of chronic arthralgia in patients overall as 
studies:
–Almost exclusively included persons who sought health care (i.e., likely more severe disease)
–Do not account for background rate of arthralgia in population
Summary
Difficult to provide precise estimate of incidence of long- term joint pain 
after chikungunya
Percentages with long -term joint pain likely variable based on severity of 
acute illness, age, sex, comorbidities
Long -term joint pain important complication of chikungunya that could be 
prevented by vaccination